Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
-0.06 (-3.23%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.75 - 1.90
52 week 1.65 - 7.77
Open 1.89
Vol / Avg. 2.61M/5.41M
Mkt cap 212.18M
P/E     -
Div/yield     -
EPS -0.78
Shares 117.88M
Beta 0.74
Inst. own 22%
May 7, 2014
Galena Biopharma Inc at Deutsche Bank Healthcare Conference Add to calendar
May 6, 2014
Q1 2014 Galena Biopharma Inc Earnings Release - 4:00PM EDT - Add to calendar
Apr 8, 2014
Galena Biopharma Inc at Needham Life Sciences Conference
Mar 28, 2014
Galena Biopharma Inc at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference
Mar 27, 2014
Galena Biopharma Inc at Maidstone Life Sciences LLC Cancer Immunotherapy: A Long Awaited Reality Conference
Mar 17, 2014
Q4 2013 Galena Biopharma Inc Earnings Release
Mar 10, 2014
Galena Biopharma Inc at ROTH Conference
Feb 12, 2014
Galena Biopharma Inc at Leerink Swann Global Healthcare Conference
Feb 10, 2014
Galena Biopharma Inc at Biotechnology Industry Organization CEO & Investor Conference - Webcast
Jan 20, 2014
Galena Biopharma Inc at Noble Financial Equity Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -3682.69% -3083.15%
Operating margin -965.60% -1397.91%
EBITD margin - -1342.50%
Return on average assets -217.08% -107.27%
Return on average equity -960.53% -455.85%
Employees 12 -
CDP Score - -


United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). In January 2014, Galena Biopharma Inc acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.

Officers and directors

Sanford J. Hillsberg J.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Mark J. Ahn Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Ryan M. Dunlap Director - Finance, Controller, Corporate Secretary
Age: 43
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. Chief Operating Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Rosemary Mazanet M.D., Ph.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 63
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven A. Kriegsman Independent Director
Age: 71
Bio & Compensation  - Reuters
Rudolph Nisi M.D. Independent Director
Age: 81
Bio & Compensation  - Reuters